Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ESPR NASDAQ:ETNB NASDAQ:MESO NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$2.71+0.9%$2.56$0.69▼$3.94$545.38M0.965.32 million shs1.87 million shsETNB89BIO$14.82+0.1%$11.95$4.16▼$15.06$2.20B1.272.83 million shs1.34 million shsMESOMesoblast$16.95-0.9%$16.21$7.09▼$22.00$2.17B2.3275,100 shs56,561 shsSRPTSarepta Therapeutics$22.41+2.4%$19.88$10.41▼$138.81$2.20B0.516.24 million shs1.29 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics-1.47%+1.13%+8.06%+77.48%+30.73%ETNB89BIO0.00%+0.20%+0.41%+54.33%+89.50%MESOMesoblast-0.47%-5.47%+4.84%+4.52%+82.50%SRPTSarepta Therapeutics-2.58%-6.21%+22.09%+83.49%-83.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeESPREsperion Therapeutics$2.71+0.9%$2.56$0.69▼$3.94$545.38M0.965.32 million shs1.87 million shsETNB89BIO$14.82+0.1%$11.95$4.16▼$15.06$2.20B1.272.83 million shs1.34 million shsMESOMesoblast$16.95-0.9%$16.21$7.09▼$22.00$2.17B2.3275,100 shs56,561 shsSRPTSarepta Therapeutics$22.41+2.4%$19.88$10.41▼$138.81$2.20B0.516.24 million shs1.29 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceESPREsperion Therapeutics-1.47%+1.13%+8.06%+77.48%+30.73%ETNB89BIO0.00%+0.20%+0.41%+54.33%+89.50%MESOMesoblast-0.47%-5.47%+4.84%+4.52%+82.50%SRPTSarepta Therapeutics-2.58%-6.21%+22.09%+83.49%-83.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceESPREsperion Therapeutics 2.50Moderate Buy$7.00158.78% UpsideETNB89BIO 2.27Hold$25.8174.23% UpsideMESOMesoblast 2.80Moderate Buy$24.0041.63% UpsideSRPTSarepta Therapeutics 2.03Hold$34.4653.77% UpsideCurrent Analyst Ratings BreakdownLatest ESPR, MESO, SRPT, and ETNB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/22/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$16.00 ➝ $18.0010/20/2025ETNB89BIOZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/14/2025SRPTSarepta TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MESOMesoblastWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SRPTSarepta TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$14.00 ➝ $16.009/27/2025ESPREsperion TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MESOMesoblastWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookESPREsperion Therapeutics$332.31M1.64$0.02 per share113.21($1.97) per share-1.37ETNB89BION/AN/AN/AN/A$3.34 per shareN/AMESOMesoblast$17.20M126.10N/AN/A$4.67 per share3.63SRPTSarepta Therapeutics$2.48B0.88$2.43 per share9.22$15.99 per share1.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateESPREsperion Therapeutics-$51.74M-$0.49N/AN/AN/A-35.84%N/A-28.41%11/6/2025 (Estimated)ETNB89BIO-$367.08M-$3.61N/AN/AN/AN/A-94.48%-80.92%11/6/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/ASRPTSarepta Therapeutics$235.24M-$0.87N/A2.05N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest ESPR, MESO, SRPT, and ETNB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ESPREsperion Therapeutics$0.06N/AN/AN/A$78.33 millionN/A11/6/2025Q3 2025ETNB89BIO-$0.50N/AN/AN/AN/AN/A11/5/2025Q3 2025SRPTSarepta Therapeutics$0.02N/AN/AN/A$331.51 millionN/A8/7/2025Q2 2025ETNB89BIO-$0.49-$0.71-$0.22-$0.71N/AN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthESPREsperion TherapeuticsN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioESPREsperion TherapeuticsN/A1.150.76ETNB89BIO0.0715.1915.19MESOMesoblast0.111.991.77SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipESPREsperion Therapeutics47.39%ETNB89BION/AMESOMesoblast1.43%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipESPREsperion Therapeutics1.70%ETNB89BIO2.60%MESOMesoblast18.80%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableETNB89BIO40148.31 million144.45 millionOptionableMESOMesoblast80128.00 million103.93 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableESPR, MESO, SRPT, and ETNB HeadlinesRecent News About These CompaniesTradr 2X Long SRPT Daily ETF1 hour ago | money.usnews.comTradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULFOctober 23 at 11:20 PM | msn.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $18.00October 23 at 9:43 AM | marketbeat.comPrivium Fund Management B.V. Makes New $698,000 Investment in Sarepta Therapeutics, Inc. $SRPTOctober 21 at 6:04 AM | marketbeat.comBlair William & Co. IL Sells 16,942 Shares of Sarepta Therapeutics, Inc. $SRPTOctober 18, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Bought by Janney Montgomery Scott LLCOctober 18, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 7% - Here's What HappenedOctober 17, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Sarepta Therapeutics (NASDAQ:SRPT)October 16, 2025 | americanbankingnews.comSarepta’s Not Done With Gene Therapy Yet as New LGMD Asset Yields Promising DataOctober 15, 2025 | biospace.comBSarepta Therapeutics (NASDAQ:SRPT) Receives Sell (D-) Rating from Weiss RatingsOctober 14, 2025 | marketbeat.comAberdeen Group plc Boosts Stake in Sarepta Therapeutics, Inc. $SRPTOctober 14, 2025 | marketbeat.comInspire Investing LLC Raises Stake in Sarepta Therapeutics, Inc. $SRPTOctober 13, 2025 | marketbeat.comCautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus FindingsOctober 13, 2025 | tipranks.comSarepta Therapeutics: A Discounted Valuation Meets Breakthrough PipelineOctober 10, 2025 | seekingalpha.comSarepta Therapeutics (SRPT) Receives a Hold from Mizuho SecuritiesOctober 10, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Buy from JefferiesOctober 10, 2025 | theglobeandmail.comWhat's Going On Sarepta Stock On Wednesday?October 8, 2025 | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst UpgradeOctober 8, 2025 | marketbeat.comRoyal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00October 8, 2025 | marketbeat.comA Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price GainsOctober 6, 2025 | finance.yahoo.com25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 CapitalOctober 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeESPR, MESO, SRPT, and ETNB Company DescriptionsEsperion Therapeutics NASDAQ:ESPR$2.70 +0.03 (+0.93%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.89BIO NASDAQ:ETNB$14.82 +0.02 (+0.10%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Mesoblast NASDAQ:MESO$16.94 -0.16 (-0.91%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Sarepta Therapeutics NASDAQ:SRPT$22.41 +0.52 (+2.37%) As of 01:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
